Dornier
Himbersor
- Desde
- 4 Mar 2020
- Mensajes
- 541
- Reputación
- 2.603
23/07/2020.Russia’s way out Microbiologist Denis Logunov explains his headstart on a cobi19 vaccine and why a two-vector approach promises better immunity.No me considero muy inteligente, pero lo que viene a decir es que usan esos adenovirus como vectores por su demostrada seguridad, pero con proteína de el bichito no??
Denis Logunov, a deputy research director at the Gamaleya Center, leads the group developing Russia’s first cobi19 vaccine.
La información sobre la banderilla "Rusa" más fiable.
Entrevista en Inglés/Ruso.
Russia’s way out Microbiologist Denis Logunov explains his headstart on a cobi19 vaccine and why a two-vector approach promises better immunity — Meduza
Первое большое интервью создатель российской вакцины от коронавируса Денис Логунов дал «Медузе». Он рассказал, стоит ли ждать прививок к сентябрю 2020 года — Meduza
Resumen de los puntos más importantes de la entrevista en Ruso/Inglés.
1.They have a vector-based Ebola vaccine registered. Worked for 3 years on a MERS vaccine. It got to phase II trials. cobi19 vaccine is based on this MERS work.
2.He emphasized that T-cell immunity is important. He says, they did experiments with different vaccine platforms, and vector-based vaccines performed much better, in particular with regard to CTLs.(cytotoxic T lymphocyte)
3.Why use two different vectors. Their vaccine is intended to be administered in two shots. They observed that this is necessary in their Ebola and MERS work. Second shot with the same vector as in the first doesn’t work due to immunity to the vector. They use two different vectors for the two shots.
4.Tested for safety in mice, rats, hamsters, rabbits, primates. Did challenge trials in hamsters and macaques and observed that animals are protected. Not yet published but they plan to publish in international journals.
5.Did human trial on 38+38 people. Planned readouts on 42 days, 3 months, 6 months after vaccination. The interview was on day 28. Plan to test for antibodies, CD4, CD8 cells. All will be published in international journals.
6.After this human trial, they expect “limited approval”. If the results don’t replicate in a larger study, the approval will be rescinded. He says, this limited approval should allow use in “risk groups” (e.g. healthcare workers). No vaccinations for kids or elderly. Will run phase III trial on 2000 people in parallel. Expect to start in August.
7.When asked about personal opinion, he says, he believes animals were protected and there is no reason to believe the vaccine won’t work. His personal worry is about how long the immunity will last and what an infection will look like after it wanes.
8.He expects mass production to start by the end of the year. His institute will be making 3-5 million doses/year by then. Several more companies are also planning to produce this vaccine.